Categoria: Adnkronos News

(Adnkronos) – BERLIN, Aug. 8, 2023 /PRNewswire/ — Following a successful run in innovative hands-free vacuum solutions, Dreame Technology, a leading innovative consumer product company that focuses on smart home appliances with the world's No.1 motor technology that offers highest RPM, has unveiled the latest addition to their robot-cleaning lineup: the L10 Prime. Seen as an upgrade on the W10, the L10 Prime combines the power of a premium vacuum with the versatility of a mop in an automated all-in-one household staple that's built for convenience. Scheduled to hit southwest European markets on 8 August, the L10 Prime is set to redefine household cleaning with its unmatched efficiency and convenience. Upgraded Mop Cleaner TechnologyThe L10 Prime autonomously toggles between cleaning modes, adjusting to different surfaces with a 7mm self-raising functionality in a display of sheer versatility. A rotary mop coupled with pressurised scrubbing effectively pick up stains, spills and unseen grains, to leave hard-wood floors polished and carpets spotless for the very best results. 2.5L Water Tank for Uninterrupted Cleaning ExperienceWorried about having to refill the tank? Don't be. Thanks to its self-refilling system, the L10 Prime ensures its generous 2.5L tank is always topped up for hours of uninterrupted cleaning, while the removable studded scrub base plate and self-cleaning function make it incredibly easy to maintain. Uncompromised Suction PowerBehind its unassuming appearance lies an extraordinary feat of domestic care. The L10 Prime doesn't hold back on vacuum suction, packing a powerful 4000Pa into an inconspicuous unit with a bristleless rubber roller brush that seamlessly untangles stray hairs and gathers debris. Purchase InformationThe L10 Prime package includes everything you need for to keep your home spic and span: 1x Gold-standard cleaning robot1x Base Station for round-the-clock charging1x Side Brush to get those corners2x Mop Pad (pre-installed)2x Mop Pad Holder1x Power Cord1x User Manual The L10 Prime will be available for online purchase Dreame's official Amazon stores in Italy, France, Germany and Spain from 8 August 2023 and will be hitting physical stores not long after. For more information, visit the Dreame Amazon store pages:Dreame Germany Amazon store
Dreame France Amazon store
Dreame Italy Amazon store
Dreame Spain Amazon store
 About DreameEstablished in 2017, Dreame Technology is an innovative consumer product company that focuses on smart home appliances with the vision to empower lives through technology. Follow us on Facebook, Instagram and Twitter. For more information please visit: https://de.dreametech.com/. Photo – https://mma.prnewswire.com/media/2167837/image_1.jpg  
View original content:https://www.prnewswire.co.uk/news-releases/dreame-unveils-l10-prime-robot-vacuum-with-upgraded-mop-cleaner-technology-301891811.html
 

 —immediapress/ictwebinfo@adnkronos.com (Web Info)

(Adnkronos) – Assorbimento rapido e più elevato di epinefrina, per un soccorso potenzialmente più rapido dei pazienti in shock anafilattico  TEL AVIV, Israele, 8 agosto 2023 /PRNewswire/ — Nasus Pharma Ltd, un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di un portafoglio di prodotti intranasali (PBI) senza ago e a base di polvere, per affrontare condizioni mediche acute, ha annunciato la pubblicazione di risultati positivi di uno studio clinico sull'epinefrina intranasale in polvere. FMXIN002 è un erogatore spray sperimentale di epinefrina in polvere per somministrazione intranasale. Non invasivo, facile da usare e affidabile, potrebbe fornire un trattamento di emergenza efficace e tempestivo in caso di gravi reazioni allergiche potenzialmente letali a cibo, farmaci e punture di insetti. Lo studio clinico fornisce ulteriori prove convincenti sulla solidità della tecnologia in polvere intranasale di Nasus Pharma già testata in altri farmaci. È importante sottolineare che la farmacocinetica dell'epinefrina intranasale a base di polvere può potenzialmente ridurre molteplici preoccupazioni recentemente sollevate all'interno della comunità medica riguardo all'adeguatezza di altre epinefrine per via intranasale per quanto riguarda la protezione nell'immediato periodo successivo allo sviluppo di shock anafilattico. "I risultati dello studio sull'epinefrina in polvere intranasale FMXIN002 di Nasus dimostrano che può fornire un soccorso più sicuro ed efficace per il trattamento di emergenza delle reazioni allergiche potenzialmente letali fornendo un dispositivo compatto facile da usare e un più rapido assorbimento dell'epinefrina", ha dichiarato la Dott.ssa Dalia Megiddo, CEO di Nasus Pharma. "La pubblicazione dei nostri risultati in un importante rivista scientifica come JACI: In Practice garantirà la diffusione della promessa di FMXIN002 all'interno della comunità medica competente." Lo studio clinico FMXIN002 è stato uno studio di biodisponibilità comparativa in aperto, a dose ascendente, in due periodi e tre trattamenti progettato per confrontare il profilo farmacocinetico di FMXIN002 con l'attuale standard di cura: un autoiniettore di epinefrina intramuscolare. (EpiPen®, Mylan ) Dodici (12) volontari affetti da allergie stagionali note hanno ricevuto un trattamento in tre sequenze con 0,3 mg di epinefrina intramuscolare mediante autoiniettore o FMXIN002 in dosi da 1,6 e 3,2 mg. Ogni dose somministrata per via intranasale è stata testata in condizioni normali o mediante test di provocazione nasale in cui è stata creata la congestione nasale per simulare condizioni analoghe all'anafilassi. I risultati dimostrano che l'esposizione (AUC0-T) e il livello plasmatico massimo (Cmax) di una dose da3,2 mg di FMXIN002 erano paragonabili a un'iniezione intramuscolare di 0,3 mg di epinefrina in normali condizioni nasali. Inoltre, FMXIN002 ha mostrato un profilo farmacocinetico significativamente superiore, specialmente durante i primi 30 minuti con congestioni nasali indotte che si verificano durante gravi reazioni allergiche: il Cmax è stato doppio rispetto a quello dell'autoiniettore intramuscolare (1110 vs. 551). AUC (0-8 ore) è stato più elevato del 56% (672 vs. 431). Il tempo impiegato per raggiungere il livello plasmatico massimo (Tmax) e il tempo per raggiungere i 100 pg/mL di una dose da 3,2 mg di FMXIM001 sono stati significativamente più rapidi dell'iniezione intramuscolare. Il T max mediano per iniezione intramuscolare è stato di 9,0 minuti rispetto ai 2,5 minuti per 3,2 mg di FMXIN002 in condizioni di congestione nasale. Il tempo medio a 100 pg/mL è stato di 3,0 minuti in condizioni normali e di 1,0 minuti in presenza di allergeni che rappresentano le condizioni reali del naso in gravi reazioni allergiche per il FMXIN002. Il tempo a 100 pg/mL è considerato la soglia clinica in cui iniziano a verificarsi risposte farmacodinamiche. Questi risultati indicano che FMXIN002 può fornire un rapido soccorso senza precedenti con un dispositivo non invasivo di facile utilizzo per reazioni allergiche potenzialmente letali. Il trattamento è stato ben tollerato. Non vi sono stati   effetti collaterali significativi e nessun cambiamento   significativo dei parametri fisiologici. Prof Yuval Tal MD PhD, Direttore dell'Allergy and Clinical Immunology Unit presso l' Hadassah Medical Center, responsabile dello studio, ha aggiunto: "In caso di grave reazione allergica potenzialmente letale, la finestra temporale terapeutica è molto breve ed è necessario un soccorso immediato con epinefrina. Pertanto, la farmacocinetica/farmacodinamica del salvataggio con epinefrina è estremamente importante. La mancata somministrazione tempestiva dell'epinefrina è stata identificata come il fattore più importante che contribuisce alla morte per anafilassi. I genitori e gli operatori sanitari spesso esitano quando si tratta di fare iniezioni. Gli adolescenti non sono disposti a portare con sé il grosso pacchetto di due iniezioni e purtroppo rappresentano una significativa percentuale dei casi di morte. Un inalatore nasale di dimensioni facili da usare può fare la vera differenza per la terapia di soccorso in caso di reazioni allergiche potenzialmente letali. Questo, oltre al tempo significativamente più breve per raggiungere i livelli ematici terapeutici e alla maggiore esposizione al farmaco nella prima mezz'ora critica, indica che FMXIN002 potrebbe cambiare drasticamente il rischio di mortalità associato all'anafilassi." Questo studio pilota indica che l'epinefrina intranasale in polvere può offrire vantaggi clinici significativi, rispetto alla via di somministrazione intramuscolare attualmente disponibile e ad altri programmi di epinefrina intranasale in soluzione in fase di sviluppo. I prodotti in polvere sono noti anche per la migliore stabilità rispetto a quelli in soluzione. Un ulteriore vantaggio della formulazione in polvere dell'epinefrina, un farmaco che subisce una rapida degradazione nelle forme di dosaggio liquide a breve durata attualmente disponibili. Informazioni su FMXIN002  FMXIN002 è una formulazione in polvere di epinefrina in spray nasale sviluppata da  Nasus Pharma grazie alla sua esclusiva tecnologia proprietaria di polvere intranasale. L'azienda ritiene che il FMXIN002 possa consentire alle persone di somministrare l'epinefrina in situazioni di emergenza in modo più facile e più rapido, e con meno esitazioni, all'insorgere di una reazione allergica, rispetto agli autoiniettori di epinefrina attualmente disponibili. FMXIN002 utilizza il dispositivo monodose per polvere nasale APTAR, un dispositivo intuitivo e facile da usare con funzionalità a 360° e una somministrazione monodose precisa del farmaco per via nasale. L'anafilassi è una reazione allergica grave, pericolosa per la vita, con un esordio improvviso che può verificarsi nel giro di pochi minuti e, se non trattata tempestivamente, può essere fatale. Circa 5 milioni di persone negli Stati Uniti sono a rischio anafilassi. Ogni anno si registrano oltre 200.000 visite al pronto soccorso per reazioni gravi dovute ad allergie alimentari. Informazioni su Nasus Pharma  Sulla base della sua esclusiva tecnologia Faster  a microsfere, Nasus Pharma sta sviluppando una serie di prodotti intranasali in polvere volti ad assistere i pazienti in diverse situazioni di emergenza acuta, come l'overdose di oppioidi e lo shock anafilattico. La somministrazione intranasale è più adatta alle situazioni in cui è richiesta una somministrazione rapida di farmaci e offre molteplici vantaggi, come la somministrazione rapida di farmaci, la facilità di utilizzo, la non invasività e la sicurezza. Il portafoglio di Nasus comprende una serie di programmi: il Naloxone intranasale, che ha completato lo studio cardine, l'Epinefrina intranasale (fase 2), oltre a una serie di programmi POC preclinici. Contatto:  
Info@nasuspharma.com Nasus Pharma Ltd. Israelehttps://www.nasuspharma.com
 Logo: https://mma.prnewswire.com/media/1485582/Nasus_Pharma_Logo.jpg
   
View original content:https://www.prnewswire.com/news-releases/nasus-pharma-annuncia-la-pubblicazione-dei-risultati-clinici-positivi-ottenuti-con-lo-spray-di-epinefrina-in-polvere-intranasale-fmxin002-sul-journal-of-allergy-and-clinical-immunology-in-practice-301895377.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

(Adnkronos) – MANCHESTER, England, Aug. 8, 2023 /PRNewswire/ — Shred-it, a Stericycle solution and leading information security service provider (Nasdaq: SRCL), has announced a two-year collaboration with one of the world's greatest professional skateboarders, Tony Hawk. The multi-tiered, global partnership includes events, digital and social media activations over the two-year term. Cory White, executive vice president and chief commercial officer at Stericycle said: "Shred-it and Tony Hawk both represent committed, passionate professionals at the top of their 'shred' games. We are thrilled to partner our Shred-it brand with Tony's brand. "As shredding pros, albeit very different types, the partnership is a natural fit and another way to engage with residential and business customers to highlight the important issue of protecting personal information." Tony Hawk is a legendary skateboarder, entrepreneur and founder of The Skatepark Project. He became a pro skateboarder at the age of 14, and by 16, was considered the best competitive skateboarder on Earth. A World Champion for 12 years in a row, he continues to skate demos, exhibitions and competitions internationally and remains the most recognized action sports figure in the world. Tony said: "I'm excited to partner with the pros at Shred-it. I've been safely shredding skate ramps for years but when it comes to safely shredding personal information, I'm a total amateur. By teaming up with Shred-it, we're helping to raise awareness about the importance of physical data destruction to help protect against identify theft."     As data protection requirements and information security best practices continue to evolve, Shred-it works with businesses across the UK and the world to protect what matters. In 2022 alone, Shred-it securely shredded and recycled 454,000 tonnes of paper — helping to safeguard both our customers' confidential information and the environment. About Shred-it: Shred-it is a Stericycle solution that helps organisations maintain the security and integrity of private and confidential information through document shredding and recycling, hard drive destruction and workplace privacy policies. As one of the largest document destruction providers in the world, Shred-it is working to shape a healthier and safer world for everyone, everywhere, every day with safe, responsible, and sustainable services and products.  For more information, please visit: www.shredit.co.uk, www.shredit.fr, www.shredit.de, www.shredit.be, www.shredit.ie, www.shredit.es, www.shredit.pt
 About Tony Hawk Inc. After more than 30 years of building a global brand ranging from apparel, toys, events, endorsements, social media, film production, and one of the most successful video game franchises ever, legendary pro-skateboarder Tony Hawk remains one of the most popular athletes in the world. Hawk's foundation, The Skatepark Project, helps finance public skateparks in underserved communities across the USA and other parts of the world. And he still skates regularly. To learn more about Tony Hawk visit tonyhawk.com. For media enquiries, please contact:Media team+44 7875416957pressoffice@stericycle.com
 Logo – https://mma.prnewswire.com/media/1667994/Shred_it_Logo.jpg  
View original content:https://www.prnewswire.co.uk/news-releases/professional-shredders-shred-it-and-tony-hawk-team-up-to-raise-awareness-of-consumer-fraud-and-identity-theft-301893861.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

(Adnkronos) – Rapid and higher epinephrine absorption – for potentially quicker rescue of patients in anaphylactic shock TEL AVIV, Israel, Aug. 8, 2023 /PRNewswire/ — Nasus Pharma Ltd a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based Intranasal (PBI) product portfolio, to address acute medical conditions announced the publication of positive results from a clinical study of intranasal powder-based Epinephrine. FMXIN002 is an investigational intranasal epinephrine powder spray device that is noninvasive, user-friendly and reliable and could provide timely effective rescue for severe potentially life-threatening allergic reactions to food, medications and insect bites. The clinical study provides additional compelling evidence to the robustness of Nasus Pharma's intranasal powder technology already tested in other drugs. Importantly the pharmacokinetics of the powder-based intranasal epinephrine can potentially abate multiple concerns recently raised within the medical community as to the adequacy of other intranasal solution-based epinephrine with regards to protection in the immediate period following anaphylactic shock development. "The results of Nasus's FMXIN002 powder intranasal epinephrine study show that it can provide a safer and more effective rescue for the emergency treatment of life-threatening allergic reactions by providing a compact easy-to-use device and quicker absorption of Epinephrine," said Dr. Dalia Megiddo. Nasus Pharma CEO. "The publication of our results in a prominent scientific journal such as JACI: In Practice will ensure the dissemination of FMXIN002's promise within the relevant medical community." The FMXIN002 clinical study was an open-label, ascending dose, two-period, three-treatment, comparative bioavailability study designed to compare the PK profile of FMXIN002 with the current standard of care- an intramuscular epinephrine autoinjector. (EpiPen® , Mylan ) Twelve (12) volunteers with known seasonal allergies received three-sequenced treatment with either 0.3 mg IM epinephrine via an autoinjector or FMXIN002 in dosages of 1.6 and 3.2 mg. Each intranasal dosage was tested under normal conditions and under nasal allergen challenge in which nasal congestion was created to simulate the congestion of the nose in anaphylaxis. The results demonstrate that the exposure (AUC0-t) and maximum plasma level (Cmax) of a 3.2 mg FMXIN002 dose was comparable to a 0.3 mg IM injection of epinephrine under normal nasal conditions. Moreover FMXIN002 showed a significantly superior PK profile especially during the first 30 minutes under induced nasal congestions that occurs in severe allergic reactions: Cmax was double, compared to IM autoinjector (1110 vs. 551). AUC (0-8h ) was 56% higher (672 vs. 431). The time to maximum plasma level (Tmax) and time to 100 pg/mL of a 3.2 mg FMXIM001 dose was significantly faster than IM injection. Median T max for IM injection was 9.0 minutes compared to 2.5 minutes for 3.2 mg FMXIN002 under nasal congestion conditions. Median Time to 100 pg/mL was 3.0 minutes under normal conditions and 1.0 minutes under allergenic challenge that represents the real-life conditions of the nose in severe allergic reaction for FMXIN002. The time to 100 pg/mL is considered to be the clinical threshold where pharmacodynamic responses begins to occur. These findings indicate that FMXIN002 can provide an unprecedented quick rescue with a non-invasive easy to use device for life threatening allergic reactions. The treatment was well tolerated. There were no significant side effects and no significant  changes physiological parameters. Prof Yuval Tal MD PhD, Director of Allergy and Clinical Immunology unit at Hadassah Medical Center who headed the study added: "In cases of severe life-threatening allergic reaction the therapeutic time window is very short and immediate rescue with epinephrine is required. Therefore, the pharmacokinetics/pharmacodynamics of epinephrine rescue are extremely important. Failure to administer epinephrine promptly has been identified as the most important factor contributing to death from anaphylaxis. Parents and care givers are often hesitant to give injections. Teenagers are averse to carry the bulky two injection package with them at all times and are sadly over-represented in fatality cases. A pocket-size user-friendly nasal inhaler could make the much-needed difference sorely needed for rescue therapy of life-threatening allergic reactions. This, in addition to the significantly shorter time to therapeutic blood levels and higher drug exposure in the critical first half an hour indicate that FMXIN002 could change dramatically the fatality risk associated with anaphylaxis." This pilot study indicates that powder-based intranasal epinephrine can offer significant clinical advantages, as compared to the currently-available intramuscular route of drug administration and other solution-based intranasal epinephrine programs in development. Powder-based products are also known to have better stability, as compared to the solution-based products. Yet an additional advantage for powder-based formulation of epinephrine, a drug that undergoes rapid degradation in the currently-available short shelf-life liquid dosage forms. About FMXIN002 FMXIN002 is a powder formulation of epinephrine nasal spray developed by Nasus Pharma based on its unique intranasal powder proprietary technology. The company believes that the FMXIN002 may enable people to deliver epinephrine in emergency situations easily, rapidly, and with less hesitation, at the onset of an allergic reaction, as compared to currently available epinephrine auto-injectors. FMXIN002 uses APTAR Nasal Unidose Powder device – an intuitive and easy-to-use device with 360° functionality and precise one-dose nasal drug delivery. Anaphylaxis is a severe, life-threatening allergic reaction with a sudden onset that can occur within a few minutes—and unless treated promptly could be fatal Some 5 million people in the United States are at risk of having an anaphylaxis reaction. Over 200,000 emergency room visits due to severe reactions from food allergies are reported annually. About Nasus Pharma Based on its unique microsphere technology, Nasus Pharma is developing a number of intranasal powder products aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers multiple advantages such as rapid drug delivery, ease of use, non-invasiveness, and safety. Nasus portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs. Contact:  
Info@nasuspharma.com Nasus Pharma Ltd. Israelhttps://www.nasuspharma.com
 Logo: https://mma.prnewswire.com/media/1485582/Nasus_Pharma_Logo.jpg    
View original content:https://www.prnewswire.co.uk/news-releases/nasus-pharma-announces-publication-of-its-positive-clinical-results-with-fmxin002-intranasal-powder-epinephrine-spray-in-the-journal-of-allergy-and-clinical-immunology-in-practice-301895373.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

(Adnkronos) – LOS ANGELES, Aug. 8, 2023 /PRNewswire/ — ENGWE, the global well-known electric bike manufacturer, is thrilled to announce the launch of its X Series E-Bikes- X26, X24, and X20. Building on the incredible success of the X26 e-bike, which raised an astounding $1,000,000 on Indiegogo in 2022, ENGWE is pushing the boundaries of electric biking with the advanced X26 and introducing the new X24 and X20 models." An Exclusive Celebration Offer: Early-Bird Pricing and Exciting Gifts Await To mark this momentous occasion, ENGWE invites biking enthusiasts to join in the celebration. By signing up, customers will have the exclusive opportunity to enjoy early-bird prices with an incredible discount of €150 off or $100 off on any ENGWE X-series e-bike. As an additional treat, participants will stand a chance to win one of the 100 special gifts. The X-Series: Choose Your Adventure ENGWE's X26, X24, and X20 e-bikes are revolutionizing short trips, offering riders a versatile and thrilling experience on the road. The naming of these models corresponds to their tire sizes – 26 inches, 24 inches, and 20 inches – allowing customers to choose the perfect fit based on their specific needs and preferences. Notably, the X24 e-bike has captured considerable attention, thanks to its exceptional cost-performance ratio. ENGWE X24 -The best powerful fat tire e-bike under $2000 Join the celebration, grab your discount and gift. Visit ENGWE's official US and EU website today to explore the X-Series and embark on an electrifying journey to explore a new way. Photo – https://mma.prnewswire.com/media/2171346/ENGWE_Release_X_series_e_bikes__ENGWE_X26__X24__X20.jpg
 
View original content:https://www.prnewswire.co.uk/news-releases/engwe-introduces-the-x-series-next-generation-e-bikes-for-unparalleled-adventures-301895406.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

(Adnkronos) – SINGAPORE, Aug. 8, 2023 /PRNewswire/ — TerraPay, a leading global payments infrastructure company, has secured an In-Principle Approval for a Major Payment Institution (MPI) license from the Monetary Authority of Singapore (MAS), marking a significant step towards being a payments company with the most regulatory approvals. With this coveted approval from MAS, a key financial services regulator, TerraPay's customers and leading global enterprises will be able to access its expansive network, across 120 receive countries and 208 send countries while enabling fully compliant, affordable, and seamless cross-border money movement. TerraPay, with regulatory approvals in 28 countries, facilitates fully compliant international money transfers, frictionless business pay-outs, and alternative payment methods. Singapore has always been a strategic region for TerraPay as it derives almost 50% of its revenues from Asia. With Singapore's position as a gateway to high-growth markets of Southeast Asia, TerraPay will capitalize on this license to tap into the immense potential of the region and bolster its existing local presence and partnerships across Singapore, South Korea, Vietnam and Philippines. On securing the approval, Ambar Sur, Founder and CEO, TerraPay said "I am incredibly proud of the comprehensive network of partners, employees, countries, and licenses we have established worldwide, enabling us to offer simplified payment services for everyone. Obtaining the approval in Singapore is a game-changer, solidifying our position as a leading cross-border payments powerhouse in one of the most significant financial markets globally. At TerraPay, our core values revolve around inclusion and innovation. We are inspired by Singapore's fintech journey, which aligns perfectly with our mission to improve lives and contribute to a dynamic, inclusive economy. The approval from MAS reinforces our commitment to excellence as we aim to become the most regulatory-approved payments company in the world."  Backed by Prime, IFC, Partech Africa & Visa, TerraPay is enabling secure real-time global payment corridors across Asia, Africa, Europe, the Middle East, and the USA, and expanding rapidly in Latin America. In May 2023, TerraPay announced its Series B equity financing round, where it successfully raised more than $100 million for global expansion plans, enabling the company to strengthen its existing pay-out network, and expand its regulatory and compliance capabilities and infrastructure globally.  About TerraPay Headquartered in the United Kingdom, TerraPay believes that the smallest payment deserves a borderless journey as safe as the largest. The group has been building an ever-expanding payments highway that empowers businesses to create transparent customer experiences with an uninterrupted, secure, and real-time global passage for every payment, however small or large. Registered and regulated across 28 global markets, TerraPay is one of the leading global partners to banks, mobile wallets, money transfer operators, merchants, and financial institutions, creating a more expansive and inclusive international financial ecosystem. With its vast network of 7.5Bn+ bank accounts, 2.1Bn+ mobile wallets, across 120 receive countries and 208 send countries, TerraPay enables its partners to drive global financial inclusion at scale. Logo: https://mma.prnewswire.com/media/1222771/TerraPay_Logo.jpg
 
View original content:https://www.prnewswire.co.uk/news-releases/terrapay-receives-in-principle-approval-for-an-mpi-license-from-the-monetary-authority-of-singapore-mas-301894604.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)